Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome.
BACKGROUND
The prognosis of patients with peritoneal tumors has been improved by the association of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, though still with an unclear impact on patients' quality of life. The purpose of our study was to evaluate the quality of life in 18 cases submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and particularly to identify the factors that influence it.


METHODS
Quality of life was evaluated using the functional assessment of cancer therapy; the results were correlated with 25 parameters.


RESULTS
The study demonstrated that the patients'quality of life was not modified by treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; the dose of mitomycin C, the site of the primary tumor, gastrointestinal, renal and neurological toxicity, adjuvant chemotherapy, the patients' age and leukopenia were factors that influenced the quality of life.


CONCLUSIONS
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy allows conservation of preoperative quality of life.
Macrì
A
A
Emergency Surgery Unit, University of Messina, Messina, Italy. amacri@unime.it
Maugeri
I
I
Trimarchi
G
G
Caminiti
R
R
Saffioti
M C
MC
Incardona
S
S
Sinardi
A
A
Irato
S
S
Altavilla
G
G
Adamo
V
V
Versaci
A
A
Famulari
C
C
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000473:pathology / Q000523:psychology / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000473:pathology / Q000523:psychology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010529:Peritoneal Cavity / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000523:psychology / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000473:pathology / Q000523:psychology / Q000628:therapy*; D011795:Surveys and Questionnaires
D016685:Mitomycin; D016190:Carboplatin; D017239:Paclitaxel